WallStSmart

Harrow Health Inc (HROW)vsMerck & Company Inc (MRK)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Merck & Company Inc generates 24379% more annual revenue ($65.77B vs $268.68M). MRK leads profitability with a 13.6% profit margin vs -5.6%. MRK earns a higher WallStSmart Score of 50/100 (D+).

HROW

Avoid

17

out of 100

Grade: F

Growth: 4.7Profit: 3.0Value: 5.0Quality: 4.5
Piotroski: 4/9Altman Z: 0.89

MRK

Hold

50

out of 100

Grade: D+

Growth: 3.3Profit: 8.0Value: 2.7Quality: 5.0
Piotroski: 3/9Altman Z: 2.30
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for HROW.

MRKSignificantly Overvalued (-49.3%)

Margin of Safety

-49.3%

Fair Value

$80.88

Current Price

$120.79

$39.91 premium

UndervaluedFair: $80.88Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

HROW0 strengths · Avg: 0/10

No standout strengths identified

MRK3 strengths · Avg: 9.3/10
Market CapQuality
$285.64B10/10

Mega-cap, among the largest globally

Operating MarginProfitability
38.6%10/10

Strong operational efficiency at 38.6%

Free Cash FlowQuality
$2.93B8/10

Generating 2.9B in free cash flow

Areas to Watch

HROW4 concerns · Avg: 2.3/10
Market CapQuality
$1.31B3/10

Smaller company, higher risk/reward

Price/BookValuation
45.1x2/10

Trading at 45.1x book value

Return on EquityProfitability
-35.4%2/10

ROE of -35.4% — below average capital efficiency

Revenue GrowthGrowth
-7.6%2/10

Revenue declined 7.6%

MRK4 concerns · Avg: 3.5/10
P/E RatioValuation
32.6x4/10

Premium valuation, high expectations priced in

Revenue GrowthGrowth
4.9%4/10

4.9% revenue growth

Debt/EquityHealth
1.073/10

Elevated debt levels

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Comparative Analysis Report

WallStSmart Research

Bull Case : HROW

HROW has a balanced fundamental profile.

Bull Case : MRK

The strongest argument for MRK centers on Market Cap, Operating Margin, Free Cash Flow.

Bear Case : HROW

The primary concerns for HROW are Market Cap, Price/Book, Return on Equity. Debt-to-equity of 10.47 is elevated, increasing financial risk.

Bear Case : MRK

The primary concerns for MRK are P/E Ratio, Revenue Growth, Debt/Equity.

Key Dynamics to Monitor

HROW profiles as a turnaround stock while MRK is a value play — different risk/reward profiles.

HROW carries more volatility with a beta of 0.34 — expect wider price swings.

MRK is growing revenue faster at 4.9% — sustainability is the question.

MRK generates stronger free cash flow (2.9B), providing more financial flexibility.

Bottom Line

MRK scores higher overall (50/100 vs 17/100). Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Harrow Health Inc

HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA

Harrow Health, Inc. is an ophthalmology-focused healthcare company. The company is headquartered in San Diego, California.

Merck & Company Inc

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.

Visit Website →

Want to dig deeper into these stocks?